Clinical Trials Browser

Interventional × Chromosome 5q Deletion Syndrome × 1 year × Clear all

NCT01869114 2025-12-10

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Phase 2 Completed

57 enrolled 13 charts

Other hematologic neoplasm

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Leukemia, Myeloid, Acute